Home/Indications/Metabolic/Type 2 Diabetes

Type 2 Diabetes

Metabolic 7 original drugs

Novel Drugs

Reformulations

Drug Targets

Metabolic indication. Type 2 Diabetes has 7 FDA-approved novel treatments, led by SANOFI-AVENTIS US, with 292 active industry clinical trials across 22 drug targets. Explore market leaders, treatments by mechanism, the clinical pipeline, and drug targets below.

Type 2 Diabetes Market Leaders

Companies with the most FDA-approved novel Type 2 Diabetes drugs.

Phase 3 Readouts Pro

12 active Phase 3 trials with confidence-graded completion dates.

Full calendar →

Q3 2026

BGM0504

BrightGene Bio-Medical Technology Co., Ltd.

Estimated · aging NCT07064486

Q3 2026

MADALENA ASSOCIATION

EMS

Estimated · aging NCT04670666

Q3 2026

GZR18

Gan & Lee Pharmaceuticals.

Estimated · aging NCT06777238

Unlock 9 more readouts with confidence-graded estimates

Upgrade to Pro

Anchored on CT.gov primary completion date. Topline announcements typically precede this by 3–9 months. Confidence labels combine date type (ACTUAL/ESTIMATED) with last-update freshness.

Type 2 Diabetes Treatments by Mechanism

Top 12 mechanisms across 350 industry trials with a known mechanism of action.

See full pipeline →

Glucose-dependent Insulinotropic Polypeptide Receptor Agonist

29 trials 6 active 2 sponsors

GLP-1 Receptor Agonist

107 trials 3 active 3 sponsors

Sodium-Glucose Cotransporter 2 Inhibitor

68 trials 7 sponsors

Insulin Analog

67 trials 4 sponsors

Dipeptidyl Peptidase 4 Inhibitor

37 trials 3 sponsors

SGLT2

10 trials 4 sponsors

DPP-4

9 trials 2 sponsors

Anti-anginal

7 trials 1 sponsor

Sulfonylurea

6 trials 4 sponsors

DPP-4/SGLT2

6 trials 1 sponsor

HMG-CoA Reductase Inhibitor

3 trials 3 sponsors

Glinide

1 trials 1 sponsor

MoA derived from FDA pharmClassEpc when intervention matches an approved drug. Codenamed clinical-stage assets without an approved counterpart show "—" and aren't grouped here — they're still in the phase tables below.

Type 2 Diabetes Clinical Pipeline by Phase

1930 industry-sponsored trials across 278 sponsors

View full landscape →

Showing 100 of 237 trials (top 100 by completion date — export for full list)

Sponsor	Asset	MoA	Status	Primary Completion	NCT
Novo Nordisk	Insulin icodec	—	RECRUITING	2026-08-04	NCT07112339
Sanofi	iGlarLixi (insulin glargine/lixisenatide)	—	RECRUITING	2026-09-18	NCT06671587
Boryung Pharmaceutical Co., Ltd	Metformin	—	RECRUITING	2026-10-01	NCT06972732
JW Pharmaceutical	Empagliflozin/Metformin	—	RECRUITING	2027-03-31	NCT07442006
Sequence LifeScience, Inc.	—	—	RECRUITING	2027-07	NCT07086443
Applied Biologics, LLC	—	—	RECRUITING	2027-08	NCT07159282
Eli Lilly	Tirzepatide	Glucose-dependent Insulinotropic Polypeptide Receptor Agonist [EPC]	RECRUITING	2027-10	NCT07438444
Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.	Metformin	—	RECRUITING	2027-12-31	NCT07244003
DexCom, Inc.	—	—	ACTIVE NOT RECRUITING	2026-11-02	NCT07603284
Eli Lilly	Tirzepatide	Glucose-dependent Insulinotropic Polypeptide Receptor Agonist [EPC]	ACTIVE NOT RECRUITING	2025-10-21	NCT05433584
Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.	ganagliflozin	—	NOT YET RECRUITING	2031-10-30	NCT07116928
Sanofi	iGlarLixi (insulin glargine/lixisenatide)	—	COMPLETED	2026-06-12	NCT06716424
Eli Lilly	Tirzepatide	Glucose-dependent Insulinotropic Polypeptide Receptor Agonist [EPC]	COMPLETED	2026-04-15	NCT06635057
Eli Lilly	Insulin Lispro-aabc	Insulin Analog [EPC]	COMPLETED	2025-09-02	NCT06370715
Bayer	Finerenone (Kerendia, BAY94-8862)	—	COMPLETED	2025-07-03	NCT05705271
AstraZeneca	Xigduo (Dapagliflozin and Metformin hydrochloride extended-release) tablets	—	COMPLETED	2025-06-30	NCT06327815
Novo Nordisk	semaglutide	GLP-1 Receptor Agonist [EPC]	COMPLETED	2025-06-18	NCT05035082
Corcept Therapeutics	Mifepristone 300 MG [Korlym]	—	COMPLETED	2024-11-19	NCT05772169
Eli Lilly	Tirzepatide	Glucose-dependent Insulinotropic Polypeptide Receptor Agonist [EPC]	COMPLETED	2024-07-15	NCT05564039
Novo Nordisk	Semaglutide	GLP-1 Receptor Agonist [EPC]	COMPLETED	2024-01-18	NCT05533632
Eli Lilly	Dulaglutide	GLP-1 Receptor Agonist [EPC]	COMPLETED	2024-01-16	NCT05659537
Celltrion Pharm, Inc.	Pioglitazone + Alogliptin	—	COMPLETED	2024-01-02	NCT03499704
Eli Lilly	Tirzepatide	Glucose-dependent Insulinotropic Polypeptide Receptor Agonist [EPC]	COMPLETED	2023-10-31	NCT05706506
Emerald Clinical Inc.	Dapagliflozin 10 MG [Farxiga]	—	COMPLETED	2023-05-30	NCT04620590
Sanofi	Insulin glargine/Lixisenatide	—	COMPLETED	2023-03-28	NCT05114590
AstraZeneca	dapagliflozin and saxagliptin	—	COMPLETED	2023-03-14	NCT04445714
Sanofi	Insulin glargine 300 U/ml	—	COMPLETED	2023-02-24	NCT05002933
Sanofi	Insulin glargine (U300)	—	COMPLETED	2022-12-23	NCT04980027
Yuhan Corporation	pregabalin sustained release tablet	—	COMPLETED	2022-12-20	NCT05624853
Getz Pharma	Insulin	—	COMPLETED	2022-11-30	NCT05161741
Boehringer Ingelheim	Empagliflozin	Sodium-Glucose Cotransporter 2 Inhibitor [EPC]	COMPLETED	2022-08-19	NCT04531462
Novo Nordisk	Semaglutide	GLP-1 Receptor Agonist [EPC]	COMPLETED	2022-06-09	NCT03596450
Getz Pharma	Metformin / Sitagliptin Oral Tablet	—	COMPLETED	2022-04-28	NCT05167513
Getz Pharma	Empagliflozin	Sodium-Glucose Cotransporter 2 Inhibitor [EPC]	COMPLETED	2021-08-10	NCT05359432
Eli Lilly	Insulin Glargine	Insulin Analog [EPC]	COMPLETED	2021-07-30	NCT04153981
Mannkind Corporation	—	—	COMPLETED	2021-05-28	NCT04849845
Sanofi	Alogliptin	—	COMPLETED	2020-12-14	NCT03794336
Sanofi	INSULIN GLARGINE (U300)	—	COMPLETED	2020-09-23	NCT03760991
JW Pharmaceutical	Anagliptin BID Treatment	—	COMPLETED	2020-09-02	NCT04810507
Yuhan Corporation	Rosuvamibe	—	COMPLETED	2020-08-12	NCT03597412
Sanofi	INSULIN GLARGINE (HOE901)	—	COMPLETED	2020-06-29	NCT03359837
Profil Institut für Stoffwechselforschung GmbH	Empagliflozin	Sodium-Glucose Cotransporter 2 Inhibitor [EPC]	COMPLETED	2020-04-20	NCT03254849
Novo Nordisk	Semaglutide	GLP-1 Receptor Agonist [EPC]	COMPLETED	2020-01-29	NCT04189848
Novo Nordisk	Insulin degludec	Insulin Analog [EPC]	COMPLETED	2019-12-20	NCT03687827
Handok Inc.	Teneligliptin	—	COMPLETED	2019-12-12	NCT03508323
AstraZeneca	Dapagliflozin	Sodium-Glucose Cotransporter 2 Inhibitor [EPC]	COMPLETED	2019-11-04	NCT03338855
Daiichi Sankyo	High-dose colesevelam	—	COMPLETED	2019-11-01	NCT01258075
AstraZeneca	Saxagliptin	—	COMPLETED	2019-08-23	NCT02917031
Novo Nordisk	liraglutide	GLP-1 Receptor Agonist [EPC]	COMPLETED	2019-08-05	NCT02730377
Eli Lilly	Dulaglutide Pen	—	COMPLETED	2019-04-12	NCT03724981
Novartis	vildagliptin	—	COMPLETED	2019-04-04	NCT01528254
Laboratoires Teriak	Clopidogrel	—	COMPLETED	2019-03-24	NCT03329261
Yuhan Corporation	Rosuvamibe® Tab	—	COMPLETED	2019-03-05	NCT03446261
Fresenius Kabi	Lactulose crystals 20 g	—	COMPLETED	2019-03-05	NCT03666546
Eli Lilly	Insulin Analog Mid Mixture	—	COMPLETED	2019-02-19	NCT03018938
Johnson & Johnson	Canagliflozin 300 mg	—	COMPLETED	2018-10-01	NCT03267576
Merck	Omarigliptin	—	COMPLETED	2018-08-21	NCT02906709
LG Chem	Gemigliptin 50mg	—	COMPLETED	2018-07-13	NCT03202563
Eli Lilly	Dulaglutide	GLP-1 Receptor Agonist [EPC]	COMPLETED	2018-06-18	NCT02750410
Eisai Inc.	Lorcaserin hydrochloride	—	COMPLETED	2018-05-14	NCT02019264
Sanofi	INSULIN GLARGINE	Insulin Analog [EPC]	COMPLETED	2018-04-26	NCT02836704
Sanofi	INSULIN GLARGINE	Insulin Analog [EPC]	COMPLETED	2018-04-20	NCT02545842
Sanofi	Irbesartan/atorvastatin fixed dose combination	—	COMPLETED	2018-04-19	NCT02842359
Orient Europharma Co., Ltd.	Mitiglinide	—	COMPLETED	2018-04	NCT04349696
Sanofi	Insulin glargine, 300 U/ml	—	COMPLETED	2018-03-02	NCT02451137
Eli Lilly	Dulaglutide	GLP-1 Receptor Agonist [EPC]	COMPLETED	2018-02-28	NCT03315780
Takeda	Trelagliptin	—	COMPLETED	2018-02-09	NCT03231709
Boehringer Ingelheim	Linagliptin	Dipeptidyl Peptidase 4 Inhibitor [EPC]	COMPLETED	2018-01-18	NCT01897532
AstraZeneca	Dapagliflozin	Sodium-Glucose Cotransporter 2 Inhibitor [EPC]	COMPLETED	2018-01-15	NCT02564926
Sanofi	INSULIN GLARGINE (U300)	—	COMPLETED	2017-12-22	NCT02954692
Novo Nordisk	—	—	COMPLETED	2017-12-09	NCT02617693
Sanofi	INSULIN GLARGINE	Insulin Analog [EPC]	COMPLETED	2017-11-27	NCT02606357
Astellas	Ipragliflozin	—	COMPLETED	2017-11-09	NCT02847091
Takeda	Trelagliptin	—	COMPLETED	2017-10-21	NCT03014479
Sanofi	insulin glargine (U300)	—	COMPLETED	2017-10-20	NCT02967211
Sanofi	insulin glargine (U300)	—	COMPLETED	2017-10-16	NCT02967224
Chemical Resources	Fenfuro	—	COMPLETED	2017-10	NCT03066089
Sanofi	Insulin glargine, 300U/mL	—	COMPLETED	2017-08-15	NCT02738151
Sanofi	Lixisenatide (AVE0010)	—	COMPLETED	2017-08-04	NCT02941367
Sanofi	insulin glargine (U300)	—	COMPLETED	2017-07-24	NCT02967237
Kowa Company, Ltd.	Tofogliflozin	—	COMPLETED	2017-07	NCT02537834
Boehringer Ingelheim	empagliflozin 10mg	—	COMPLETED	2017-06-02	NCT02589626
Takeda	Trelagliptin	—	COMPLETED	2017-04-27	NCT02771093
Boehringer Ingelheim	Empagliflozin	Sodium-Glucose Cotransporter 2 Inhibitor [EPC]	COMPLETED	2017-04-18	NCT02589639
Boehringer Ingelheim	linagliptin	Dipeptidyl Peptidase 4 Inhibitor [EPC]	COMPLETED	2017-04-18	NCT02240680
Novartis	—	—	COMPLETED	2017-04-06	NCT02670928
Novo Nordisk	biphasic insulin aspart 30	—	COMPLETED	2017-03-18	NCT02582242
AstraZeneca	Dapagliflozin	Sodium-Glucose Cotransporter 2 Inhibitor [EPC]	COMPLETED	2017-03-13	NCT02471404
Johnson & Johnson	Canagliflozin, 100 mg	—	COMPLETED	2017-02-23	NCT01989754
AstraZeneca	Bydureon	—	COMPLETED	2016-12-07	NCT02533453
Takeda	Azilsartan Medoxomil	—	COMPLETED	2016-11-15	NCT02517866
Handok Inc.	Teneligliptin	—	COMPLETED	2016-09-26	NCT02512523
Novo Nordisk	biphasic insulin aspart 30	—	COMPLETED	2016-09-20	NCT02453685
Astellas	Ipragliflozin	—	COMPLETED	2016-07-07	NCT02291874
Bristol-Myers Squibb	Metformin XR	—	COMPLETED	2016-06-01	NCT01864174
Takeda	Metformin	—	COMPLETED	2016-06-01	NCT02049814
Dexa Medica Group	DLBS1033	—	COMPLETED	2016-06	NCT01865474
AstraZeneca	Dapagliflozin	Sodium-Glucose Cotransporter 2 Inhibitor [EPC]	COMPLETED	2016-04-28	NCT02426541
Tanabe Pharma Corporation	Canagliflozin (TA-7284)	—	COMPLETED	2016-04	NCT02622113
Takeda	Azilsartan	—	COMPLETED	2016-04	NCT02079805

Showing 100 of 697 trials (top 100 by completion date — export for full list)

Sponsor	Asset	MoA	Status	Primary Completion	NCT
BrightGene Bio-Medical Technology Co., Ltd.	BGM0504	—	RECRUITING	2026-07-31	NCT07064486
Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.	HDM1002 200 mg	—	RECRUITING	2026-10-10	NCT07193459
CMG Pharmaceutical Co. Ltd	CMG190303(Dapagliflozin/Rosuvastatin)	—	RECRUITING	2026-11-04	NCT06772168
Celltrion	Metformin	—	RECRUITING	2026-12	NCT07093476
Fujian Shengdi Pharmaceutical Co., Ltd.	HRS9531	—	RECRUITING	2027-02	NCT07060456
Hudson Biotech	Tirzepatide	Glucose-dependent Insulinotropic Polypeptide Receptor Agonist [EPC]	RECRUITING	2027-02-14	NCT07481747
Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.	HDM1002 100 mg	—	RECRUITING	2027-02-16	NCT07082114
Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.	HDM1005 1	—	RECRUITING	2027-08-28	NCT07394114
Pfizer	PF-08653944	—	RECRUITING	2027-10-12	NCT07400653
Hanmi Pharmaceutical Company Limited	HM11260C	—	RECRUITING	2027-11	NCT07379333
Eli Lilly	Dulaglutide	GLP-1 Receptor Agonist [EPC]	RECRUITING	2027-12	NCT06739122
Novo Nordisk	Cagrisema	—	RECRUITING	2028-02-23	NCT07564414
Roche	—	—	RECRUITING	2028-02-24	NCT07670416
NewAmsterdam Pharma	obicetrapib 10 mg + ezetimibe 10 mg FDC daily	—	RECRUITING	2028-03	NCT07219602
AstraZeneca	Elecoglipron	—	RECRUITING	2028-05-23	NCT07662213
AstraZeneca	Elecoglipron	—	RECRUITING	2028-07-05	NCT07662109
AstraZeneca	Elecoglipron	—	RECRUITING	2028-07-13	NCT07662135
AstraZeneca	Elecoglipron	—	RECRUITING	2028-07-14	NCT07662044
Roche	—	—	RECRUITING	2028-08-07	NCT07351058
Prokidney	Renal Autologous Cell Therapy (REACT/ rilparencel)	—	RECRUITING	2029-12	NCT05099770
Boehringer Ingelheim	Vicadrostat	—	RECRUITING	2029-12-14	NCT07064473
EMS	MADALENA ASSOCIATION	—	RECRUITING	2026-07	NCT04670666
THPharm Corp.	THP-00101	—	RECRUITING	2026-06-01	NCT06647745
Gan & Lee Pharmaceuticals.	GZR33 Injection	—	RECRUITING	2026-04-07	NCT07527078
BrightGene Bio-Medical Technology Co., Ltd.	Drug: 5 mg BGM0504 Administered SC	—	RECRUITING	2026-03-20	NCT06716216
BrightGene Bio-Medical Technology Co., Ltd.	Drug: 5 mg BGM0504 Administered SC	—	RECRUITING	2025-12-29	NCT06716203
Boryung Pharmaceutical Co., Ltd	BR1019A	—	RECRUITING	2025-04	NCT06220773
Eli Lilly	Retatrutide	—	ACTIVE NOT RECRUITING	2026-08	NCT06260722
Gan & Lee Pharmaceuticals.	GZR18	—	ACTIVE NOT RECRUITING	2026-08-07	NCT06777238
Fujian Shengdi Pharmaceutical Co., Ltd.	HRS9531 Injection	—	ACTIVE NOT RECRUITING	2026-09-30	NCT06649344
Eli Lilly	Retatrutide	—	ACTIVE NOT RECRUITING	2026-10	NCT06297603
Han Xu, M.D., Ph.D., FAPCR, Sponsor-Investigator, IRB Chair	Farxiga® (dapagliflozin) + Onglyza® (saxagliptin) + Metformin Oral Mix Treat type 2 diabetes	—	ACTIVE NOT RECRUITING	2026-10-18	NCT07033585
CSPC Ouyi Pharmaceutical Co., Ltd.	Prusogliptin, Dapagliflozin(high dose), Dapagliflozin (low dose) placebo, plus metformin XR	—	ACTIVE NOT RECRUITING	2026-10-30	NCT07026968
Gan & Lee Pharmaceuticals.	GZR18	—	ACTIVE NOT RECRUITING	2026-12-11	NCT06778967
Amgen	Maridebart cafraglutide	—	ACTIVE NOT RECRUITING	2027-01-21	NCT06858878
Novo Nordisk	Cagrilintide	—	ACTIVE NOT RECRUITING	2027-05-12	NCT07220759
Eli Lilly	Orforglipron	—	ACTIVE NOT RECRUITING	2027-08	NCT06993792
Eli Lilly	Orforglipron	—	ACTIVE NOT RECRUITING	2027-08	NCT06972472
Novo Nordisk	Semaglutide	GLP-1 Receptor Agonist [EPC]	ACTIVE NOT RECRUITING	2027-11-07	NCT03811561
Novo Nordisk	Oral semaglutide	—	ACTIVE NOT RECRUITING	2026-06-29	NCT07271251
Novo Nordisk	Cagrilintide	—	ACTIVE NOT RECRUITING	2026-06-02	NCT06534411
Beijing Dongfang Biotech Co., Ltd.	Exendin-4 Fc fusion protein injection	—	ACTIVE NOT RECRUITING	2026-05-01	NCT06254014
Eli Lilly	Retatrutide	—	ACTIVE NOT RECRUITING	2026-05	NCT05929079
Dong-A ST Co., Ltd.	DA5221-T1	—	ACTIVE NOT RECRUITING	2025-09-05	NCT06290349
Jiangsu HengRui Medicine Co., Ltd.	Noiiglutide Injection	—	ACTIVE NOT RECRUITING	2025-05-28	NCT06649773
Qilu Pharmaceutical Co., Ltd.	QLG1091	—	NOT YET RECRUITING	2026-12	NCT07487103
Guangdong Raynovent Biotech Co., Ltd	RAY1225	—	NOT YET RECRUITING	2026-12-01	NCT07139535
Guangdong Raynovent Biotech Co., Ltd	RAY1225	—	NOT YET RECRUITING	2026-12-01	NCT07139548
Jiangsu Hansoh Pharmaceutical Co., Ltd.	HS-20094 Injection	—	NOT YET RECRUITING	2027-03-30	NCT07156500
Jiangsu Hansoh Pharmaceutical Co., Ltd.	HS-20094 Injection	—	NOT YET RECRUITING	2027-03-30	NCT07156539
Oramed, Ltd.	ORMD-0801 8 mg	—	NOT YET RECRUITING	2027-04-25	NCT06731075
Eli Lilly	Orforglipron	—	NOT YET RECRUITING	2027-05	NCT07613307
Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.	HDM1005 1	—	NOT YET RECRUITING	2027-08-30	NCT07417306
The United Bio-Technology (Hengqin) Co., Ltd.	UBT251 Injection 2.0 mg	—	NOT YET RECRUITING	2027-09-24	NCT07659574
Carnot Laboratories	Bofanglutide	—	NOT YET RECRUITING	2027-10	NCT07628985
Daewoong Pharmaceutical Co. LTD.	DWP16001	—	NOT YET RECRUITING	2027-11	NCT07619833
Amgen	Maridebart Cafraglutide	—	NOT YET RECRUITING	2027-12-26	NCT07684144
The United Bio-Technology (Hengqin) Co., Ltd.	UBT251 Injection 2.0 mg group	—	NOT YET RECRUITING	2028-02-29	NCT07653477
AstraZeneca	Elecoglipron	—	NOT YET RECRUITING	2028-05-23	NCT07664553
Shandong New Time Pharmaceutical Co., LTD	F027	—	NOT YET RECRUITING	2028-08-01	NCT07046273
Novo Nordisk	NNC0487-0111	—	NOT YET RECRUITING	2028-12-12	NCT07400107
Novo Nordisk	CagriSema (Cagrilintide B and Semaglutide I)	—	NOT YET RECRUITING	2029-09-07	NCT07282613
Eli Lilly	Orforglipron	—	NOT YET RECRUITING	2030-03	NCT07668336
EMS	LID104	—	NOT YET RECRUITING	2026-05	NCT05886088
Tonghua Dongbao Pharmaceutical Co.,Ltd	Insulin Degludec/liraglutide Injection	—	NOT YET RECRUITING	2025-10	NCT06559722
Shandong Suncadia Medicine Co., Ltd.	HRS-7535 tablet	—	COMPLETED	2026-05-29	NCT06589765
Celltrion	CT-L03 Group 1	—	COMPLETED	2026-04-16	NCT06571591
Eli Lilly	Orforglipron	—	COMPLETED	2026-03-16	NCT05803421
Novo Nordisk	Cagrilintide	—	COMPLETED	2026-03-04	NCT06221969
CSPC Baike (Shandong) Biopharmaceutical Co., Ltd.	TG103	—	COMPLETED	2026-02-03	NCT06235086
CSPC Baike (Shandong) Biopharmaceutical Co., Ltd.	TG103	—	COMPLETED	2026-01-23	NCT06258148
Fujian Shengdi Pharmaceutical Co., Ltd.	HRS9531 Injection	—	COMPLETED	2026-01-21	NCT06650007
Boehringer Ingelheim	—	—	COMPLETED	2025-12-12	NCT06066528
Novo Nordisk	Cagrilintide	—	COMPLETED	2025-11-19	NCT06065540
Shandong Suncadia Medicine Co., Ltd.	HRS-7535 tablet	—	COMPLETED	2025-11-13	NCT06672172
Novo Nordisk	Cagrilintide	—	COMPLETED	2025-10-01	NCT06323174
Eli Lilly	Orforglipron	—	COMPLETED	2025-09-26	NCT06192108
Jiangsu HengRui Medicine Co., Ltd.	HR17031 injection	—	COMPLETED	2025-09-19	NCT06881264
Innovent Biologics (Suzhou) Co. Ltd.	IBI362	—	COMPLETED	2025-09-17	NCT06184568
Eli Lilly	Orforglipron	—	COMPLETED	2025-09-15	NCT06109311
Novo Nordisk	Cagrilintide	—	COMPLETED	2025-09-09	NCT06323161
Eli Lilly	Orforglipron	—	COMPLETED	2025-08-22	NCT06045221
Eli Lilly	Orforglipron	—	COMPLETED	2025-08-08	NCT05872620
HighTide Biopharma Pty Ltd	HTD1801	—	COMPLETED	2025-06-13	NCT06415773
Eli Lilly	Tirzepatide	Glucose-dependent Insulinotropic Polypeptide Receptor Agonist [EPC]	COMPLETED	2025-06-12	NCT04255433
Eli Lilly	Orforglipron	—	COMPLETED	2025-06-05	NCT06010004
Novo Nordisk	IcoSema	—	COMPLETED	2025-05-27	NCT06269107
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.	semaglutide injection (HD1916)	—	COMPLETED	2025-05-14	NCT06161844
Jiangsu HengRui Medicine Co., Ltd.	HR17031 injection	—	COMPLETED	2025-05-13	NCT06871761
Novo Nordisk	Oral semaglutide	—	COMPLETED	2025-04-29	NCT04596631
Novo Nordisk	Insulin Icodec	—	COMPLETED	2025-04-14	NCT05813912
Merck	Ertugliflozin 5 mg	—	COMPLETED	2025-04-11	NCT04029480
Eli Lilly	Orforglipron	—	COMPLETED	2025-04-03	NCT05971940
Novo Nordisk	Semaglutide	GLP-1 Receptor Agonist [EPC]	COMPLETED	2025-03-05	NCT05514535
Novo Nordisk	Cagrilintide	—	COMPLETED	2025-01-28	NCT05394519
HighTide Biopharma Pty Ltd	HTD1801	—	COMPLETED	2024-12-12	NCT06350890
HighTide Biopharma Pty Ltd	HTD1801	—	COMPLETED	2024-12-12	NCT06353347
Tonghua Dongbao Pharmaceutical Co.,Ltd	THDB0206 Injection	—	COMPLETED	2024-12-10	NCT05834868
Jiangsu HengRui Medicine Co., Ltd.	INS068 injection	—	COMPLETED	2024-11-23	NCT05699408
Novo Nordisk	Semaglutide	GLP-1 Receptor Agonist [EPC]	COMPLETED	2024-11-21	NCT04865770

Showing 100 of 367 trials (top 100 by completion date — export for full list)

Sponsor	Asset	MoA	Status	Primary Completion	NCT
Housey Healthcare ULC	HP-211	—	RECRUITING	2026-10	NCT07546929
Eli Lilly	LY3457263	—	RECRUITING	2026-12	NCT06897475
Arrowhead Pharmaceuticals	ARO-ALK7	—	RECRUITING	2027-02	NCT06937203
Eli Lilly	Macupatide	—	RECRUITING	2027-03	NCT07215559
Alnylam Pharmaceuticals	ALN-4324	—	RECRUITING	2027-05-28	NCT07465224
Biomea Fusion Inc.	icovamenib 100mg	—	RECRUITING	2027-06	NCT07502495
Biomea Fusion Inc.	icovamenib 100 mg	—	RECRUITING	2027-06	NCT07502508
Alnylam Pharmaceuticals	ALN-4324	—	RECRUITING	2027-08-31	NCT06845202
Novo Nordisk	NNC0662-0419	—	RECRUITING	2027-09-03	NCT07415954
Hanmi Pharmaceutical Company Limited	HM15275	—	RECRUITING	2027-10	NCT07527650
Novo Nordisk	UBT251	—	RECRUITING	2027-10-04	NCT07668388
Sparrow Pharmaceuticals	clofutriben	—	RECRUITING	2027-12-31	NCT07296484
Estar Medical dba Medical Technologies, LTD	—	—	RECRUITING	2026-05-15	NCT06810726
Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.	HDM1005 1	—	RECRUITING	2026-01-31	NCT07109700
Mankind Pharma Limited	MKP10241	—	RECRUITING	2026-01-19	NCT07098663
Hyundai Pharm	HD-6277 100mg	—	RECRUITING	2025-03-31	NCT06647550
Beijing Supreme Life Pharmaceutical Technology Co., Ltd.	Fuling Yunhua Granules	—	RECRUITING	2025-01-30	NCT06575478
Gan and Lee Pharmaceuticals, USA	GZR101 Injection	—	RECRUITING	2024-12	NCT06558708
Golo	—	—	RECRUITING	2024-11	NCT05844644
Ascletis Pharma (China) Co., Limited	ASC30 tablets	—	ACTIVE NOT RECRUITING	2026-08	NCT07321678
Zealand Pharma	Petrelintide	—	ACTIVE NOT RECRUITING	2026-08-13	NCT06926842
Novo Nordisk	CagriSema (Cagrilintide B and Semaglutide I)	—	ACTIVE NOT RECRUITING	2026-08-21	NCT06797869
Eli Lilly	Tirzepatide	Glucose-dependent Insulinotropic Polypeptide Receptor Agonist [EPC]	ACTIVE NOT RECRUITING	2026-09	NCT05536804
Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure Therapeutics	Aleniglipron	—	ACTIVE NOT RECRUITING	2026-09	NCT07400588
Eli Lilly	LY3938577	—	ACTIVE NOT RECRUITING	2026-11	NCT07215312
Roche	RO7795081	—	ACTIVE NOT RECRUITING	2026-11-27	NCT07112872
Jiangsu HengRui Medicine Co., Ltd.	SHR-3167 Injection	—	ACTIVE NOT RECRUITING	2026-12	NCT07472725
MediciNova	MN-001	—	ACTIVE NOT RECRUITING	2026-12-31	NCT05464784
Gan & Lee Pharmaceuticals.	GZR102	—	ACTIVE NOT RECRUITING	2026-06-28	NCT07055386
HiDO Technologies	—	—	ACTIVE NOT RECRUITING	2026-05-31	NCT06691256
Carmot Therapeutics, Inc.	Enicepatide	—	ACTIVE NOT RECRUITING	2026-05-29	NCT06628362
Jiangsu HengRui Medicine Co., Ltd.	SHR-3167	—	ACTIVE NOT RECRUITING	2026-02	NCT07018453
Eli Lilly	Tirzepatide	Glucose-dependent Insulinotropic Polypeptide Receptor Agonist [EPC]	ACTIVE NOT RECRUITING	2026-01-08	NCT06037252
Guangdong Raynovent Biotech Co., Ltd	RAY1225	—	ACTIVE NOT RECRUITING	2025-12-20	NCT06254274
Amgen	Maridebart Cafraglutide	—	ACTIVE NOT RECRUITING	2025-10-06	NCT06660173
Gan & Lee Pharmaceuticals.	GZR101-80	—	NOT YET RECRUITING	2027-02-11	NCT07387003
Fujian Shengdi Pharmaceutical Co., Ltd.	HRS9531 Tablet	—	NOT YET RECRUITING	2027-05	NCT07599410
Global Institute of Stem Cell Therapy and Research	DT2-SCT intravenous infusion	—	NOT YET RECRUITING	2028-06	NCT06789302
Gubra A/S	GUB-UCN2	—	NOT YET RECRUITING	2028-12	NCT07702890
NodThera Limited	NT-0796	—	COMPLETED	2026-05-27	NCT07055516
Jiangsu HengRui Medicine Co., Ltd.	SHR-3167	—	COMPLETED	2026-04-22	NCT06688123
Pfizer	MET097 Injection	—	COMPLETED	2025-12-29	NCT06897202
AstraZeneca	AZD5004	—	COMPLETED	2025-12-19	NCT06579105
The United Bio-Technology (Hengqin) Co., Ltd.	Semaglutide Injection (Ozempic®)	—	COMPLETED	2025-11-21	NCT07163624
Novo Nordisk	NNC0487-0111 subcutanous	—	COMPLETED	2025-10-01	NCT06542874
Eli Lilly	Retatrutide	—	COMPLETED	2025-10-01	NCT05936151
Novo Nordisk	Cagrilintide	—	COMPLETED	2025-09-24	NCT06131372
Novo Nordisk	NNC0519-0130	—	COMPLETED	2025-09-19	NCT06326047
Shandong Suncadia Medicine Co., Ltd.	HRS-7535	—	COMPLETED	2025-07-15	NCT06415214
Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.	HDM1002 50 mg	—	COMPLETED	2025-05-30	NCT06481085
Prokidney	Renal Autologous Cell Therapy (REACT)	—	COMPLETED	2025-05-20	NCT05018416
HighTide Biopharma Pty Ltd	HTD1801	—	COMPLETED	2025-04-30	NCT05623189
Bayer	Finerenone (BAY94-8862 ) 10 mg	—	COMPLETED	2025-03-14	NCT05254002
Jiangsu Hansoh Pharmaceutical Co., Ltd.	HS-20094	—	COMPLETED	2025-03-07	NCT06901648
Dongguan HEC Biopharmaceutical R&D Co., Ltd.	HEC88473, Placebo, Dulaglutide	—	COMPLETED	2025-02-27	NCT06148649
Jeil Pharmaceutical Co., Ltd.	SGLT2 inhibitor	—	COMPLETED	2024-12-23	NCT06144788
Biomea Fusion Inc.	BMF-219	—	COMPLETED	2024-11-18	NCT05731544
Shandong Suncadia Medicine Co., Ltd.	HRS-7535	—	COMPLETED	2024-11-15	NCT06393348
Amgen	Maridebart Cafraglutide	—	COMPLETED	2024-10-08	NCT05669599
Haisco Pharmaceutical Group Co., Ltd.	HSK7653 10 mg	—	COMPLETED	2024-10-05	NCT06703268
Fujian Shengdi Pharmaceutical Co., Ltd.	HRS9531 injection	—	COMPLETED	2024-09-24	NCT05966272
BrightGene Bio-Medical Technology Co., Ltd.	BGM0504 Administered SC	—	COMPLETED	2024-08-13	NCT06974825
Imbria Pharmaceuticals, Inc.	IMB-1018972	—	COMPLETED	2024-08-06	NCT04826159
Beijing QL Biopharmaceutical Co.,Ltd	ZT002 Injection	—	COMPLETED	2024-07-22	NCT07065032
Gan and Lee Pharmaceuticals, USA	GZR4 Injection	—	COMPLETED	2024-07-13	NCT06202079
Gan and Lee Pharmaceuticals, USA	GZR101	—	COMPLETED	2024-06-28	NCT06199505
Inventiva Pharma	IVA337	—	COMPLETED	2024-03-30	NCT05232071
Jiangsu Hansoh Pharmaceutical Co., Ltd.	HS-20094 5mg	—	COMPLETED	2024-01-04	NCT06118008
Prokidney	Renal Autologous Cell Therapy (REACT)	—	COMPLETED	2023-12	NCT02836574
Novo Nordisk	Semaglutide	GLP-1 Receptor Agonist [EPC]	COMPLETED	2023-10-12	NCT05486065
Gan and Lee Pharmaceuticals, USA	GZR18	—	COMPLETED	2023-09-28	NCT06256523
Hyundai Pharm	HD-6277	—	COMPLETED	2023-06-28	NCT05666128
Glyscend, Inc.	GLY-200	—	COMPLETED	2023-03-14	NCT05478525
Carmot Therapeutics, Inc.	CT-868	—	COMPLETED	2023-02-28	NCT05110846
Novo Nordisk	NNC0480-0389	—	COMPLETED	2023-02-13	NCT05144984
HighTide Biopharma Pty Ltd	HTD1801	—	COMPLETED	2023-01-17	NCT06411275
Prokidney	Renal Autologous Cell Therapy (REACT)	—	COMPLETED	2022-11-17	NCT03270956
Eli Lilly	LY3502970	—	COMPLETED	2022-09-30	NCT05048719
Eli Lilly	LY3437943	—	COMPLETED	2022-07-08	NCT04867785
Novo Nordisk	Semaglutide 2.4 mg	—	COMPLETED	2022-07-07	NCT04982575
Oramed, Ltd.	ORMD-0801 (Insulin) capsule 8 mg BD	—	COMPLETED	2022-06-27	NCT04618744
Oramed, Ltd.	ORMD-0801	—	COMPLETED	2022-06-07	NCT04564846
Jiangsu HengRui Medicine Co., Ltd.	INS068 injection	—	COMPLETED	2022-05-28	NCT04663282
Innovent Biologics (Suzhou) Co. Ltd.	IBI362	—	COMPLETED	2022-04-28	NCT04965506
AstraZeneca	Cotadutide 100 micrograms	—	COMPLETED	2022-03-08	NCT04515849
Bayer	Finerenone (Kerendia, BAY94-8862)	—	COMPLETED	2021-12-31	NCT05013008
Boehringer Ingelheim	BI 456906	—	COMPLETED	2021-10-08	NCT04153929
Eli Lilly	LY3209590	—	COMPLETED	2021-10-08	NCT04450394
Suzhou Yabao Pharmaceutical R&D Co., Ltd.	SY-004	—	COMPLETED	2021-07-09	NCT04217291
AstraZeneca	AZD9567	—	COMPLETED	2021-06-09	NCT04556760
Pfizer	PF-06882961	—	COMPLETED	2021-06-08	NCT03985293
Innovent Biologics (Suzhou) Co. Ltd.	IBI362	—	COMPLETED	2021-05-28	NCT04466904
MedImmune LLC	MEDI0382	—	COMPLETED	2021-04-14	NCT03555994
Neuraly, Inc.	NLY01	—	COMPLETED	2020-12-04	NCT04159766
Roger New	Oral insulin	—	COMPLETED	2020-07-11	NCT06473662
Jiangsu HengRui Medicine Co., Ltd.	HS-20004	—	COMPLETED	2020-06-04	NCT03848793
Eli Lilly	LY3209590	—	COMPLETED	2020-02-18	NCT03736785
HighTide Biopharma Pty Ltd	HTD1801	—	COMPLETED	2020-02-07	NCT03656744
Novo Nordisk	Semaglutide (administered by DV3396 pen)	—	COMPLETED	2020-01-04	NCT04143945
Pila Pharma	XEN-D0501	—	COMPLETED	2019-12-19	NCT05353686

Showing 100 of 629 trials (top 100 by completion date — export for full list)

Sponsor	Asset	MoA	Status	Primary Completion	NCT
Hua Medicine Limited	HMS1005	—	RECRUITING	2026-08-13	NCT07568678
Merck	MK-1403 + additive coformulation	—	RECRUITING	2026-08-28	NCT07242469
Daewoong Pharmaceutical Co. LTD.	DWRX5003	—	RECRUITING	2026-10-27	NCT07539415
Shenzhen MingSight Relin Pharmaceuticals Co., Ltd.	MS-553	—	RECRUITING	2026-10-30	NCT04187443
Eli Lilly	LY4057996 SC	—	RECRUITING	2026-12	NCT06945406
Jiangsu HengRui Medicine Co., Ltd.	SHR-3167 Injection	—	RECRUITING	2027-03	NCT07032688
Alveus Therapeutics, Inc.	ALV-100	—	RECRUITING	2027-04	NCT07399678
Novo Nordisk	NNC9733-0001	—	RECRUITING	2027-08-30	NCT07270731
Amgen	AMG 127	—	RECRUITING	2027-10-02	NCT07590193
Regend Therapeutics	REGEND003	—	RECRUITING	2027-12	NCT07275788
Novo Nordisk	NNC1679-0001	—	RECRUITING	2028-06-25	NCT07570992
Vincentage Pharma Co., Ltd	CX11 (VCT220)	—	RECRUITING	2026-06-30	NCT07349381
Gan and Lee Pharmaceuticals, USA	GZR4 injection	—	RECRUITING	2026-04-01	NCT07146347
OrsoBio, Inc	TLC-6740 Oral Solution	—	RECRUITING	2026-02	NCT05822544
1Globe Health Institute	QX1206	—	RECRUITING	2025-07	NCT06694935
Neurotronic, Inc.	—	—	RECRUITING	2025-01	NCT05369065
Neurotronic, Inc.	—	—	RECRUITING	2025-01	NCT05363761
Hyundai Pharm	Empagliflozin 25 MG	—	RECRUITING	2024-09-02	NCT06578676
AdipoPharma LLC	PATAS Trifluoroacetate	—	ACTIVE NOT RECRUITING	2026-07-30	NCT07223333
Eli Lilly	LY4086940	—	ACTIVE NOT RECRUITING	2026-08	NCT06945419
Eli Lilly	Dulaglutide	GLP-1 Receptor Agonist [EPC]	ACTIVE NOT RECRUITING	2026-08	NCT07313813
Roche	RO7204239	—	ACTIVE NOT RECRUITING	2026-09-14	NCT07137585
Eli Lilly	Tirzepatide	Glucose-dependent Insulinotropic Polypeptide Receptor Agonist [EPC]	ACTIVE NOT RECRUITING	2026-11	NCT07299084
Amgen	Maridebart cafraglutide	—	ACTIVE NOT RECRUITING	2026-11-15	NCT07160257
Celltrion	L03RD1	—	ACTIVE NOT RECRUITING	2026-05-24	NCT07533539
Eilean Therapeutics	ZE63-0302	—	ACTIVE NOT RECRUITING	2026-04-21	NCT07234864
DexCom, Inc.	Basal insulin	—	ACTIVE NOT RECRUITING	2026-01-16	NCT07681375
Gan and Lee Pharmaceuticals, USA	GZR18	—	ACTIVE NOT RECRUITING	2024-12-09	NCT06554054
Gan & Lee Pharmaceuticals.	GZR4 injection A	—	NOT YET RECRUITING	2026-07-29	NCT07670897
Nimble Science Ltd.	—	—	NOT YET RECRUITING	2026-08	NCT06704022
Fujian Shengdi Pharmaceutical Co., Ltd.	HRS9531 tablets	—	NOT YET RECRUITING	2026-09	NCT06506175
The United Bio-Technology (Hengqin) Co., Ltd.	UBT38006	—	NOT YET RECRUITING	2026-10-25	NCT07630233
Chipscreen Biosciences, Ltd.	Chiglitazar/Metformin extended-release tablets under fasting conditions	—	NOT YET RECRUITING	2026-10-26	NCT07511010
Gan & Lee Pharmaceuticals.	GZR102 injection	—	NOT YET RECRUITING	2025-09-30	NCT06974487
Gan and Lee Pharmaceuticals, USA	GZR18 and metformin	—	NOT YET RECRUITING	2025-03-19	NCT06670209
Bostal Drug Delivery Co., Ltd	Semaglutide Extended-release for Injectable Suspension, 1 mg	—	NOT YET RECRUITING	2024-11	NCT06422624
Chong Kun Dang Pharmaceutical	CKD-383(Fed)	—	NOT YET RECRUITING	2024-08-01	NCT06492655
Humanis Saglık Anonim Sirketi	Empagliflozin / Metformin Extended-Release Tablet	—	COMPLETED	2026-06-29	NCT07694115
Humanis Saglık Anonim Sirketi	Empagliflozin/Linagliptin/Metformin HCl Extended Release Tablet	—	COMPLETED	2026-06-16	NCT07691203
Merck	MK-2828	—	COMPLETED	2026-05-04	NCT07089784
Eli Lilly	Retatrutide	—	COMPLETED	2026-05-04	NCT06982846
Humanis Saglık Anonim Sirketi	Imeglimin Hydrochloride Film Coated Tablet	—	COMPLETED	2026-03-27	NCT07691177
Eli Lilly	LY3549492	—	COMPLETED	2026-03-02	NCT06869018
Novo Nordisk	NNC0471-0119 H	—	COMPLETED	2026-02-22	NCT07068295
Novo Nordisk	NNC0519-0130	—	COMPLETED	2026-01-28	NCT07004322
Eli Lilly	LY3549492	—	COMPLETED	2026-01-27	NCT07073170
Eli Lilly	LY3209590	—	COMPLETED	2026-01-02	NCT06362265
Humanis Saglık Anonim Sirketi	Empagliflozin / Metformin HCl XR Tablets	—	COMPLETED	2025-12-29	NCT07372118
Novo Nordisk	Semaglutide	GLP-1 Receptor Agonist [EPC]	COMPLETED	2025-12-28	NCT06403761
BrightGene Bio-Medical Technology Co., Ltd.	BGM0504	—	COMPLETED	2025-12-25	NCT06929156
Novo Nordisk	NNC0519-0130	—	COMPLETED	2025-12-10	NCT06567041
Eccogene	AZD5004	—	COMPLETED	2025-11-28	NCT06988553
Chong Kun Dang Pharmaceutical	CKD-383 0.25/12.5/1000mg	—	COMPLETED	2025-11-09	NCT07304726
Chong Kun Dang Pharmaceutical	CKD-383 0.5/10/1000mg	—	COMPLETED	2025-11-07	NCT07304700
Carmot Australia First Pty Ltd	CT-996	—	COMPLETED	2025-11-07	NCT05814107
Chong Kun Dang Pharmaceutical	CKD-383 0.5/25/1000mg	—	COMPLETED	2025-11-03	NCT07304687
Celltrion	L03RD1	—	COMPLETED	2025-10-03	NCT07158346
Humanis Saglık Anonim Sirketi	Empagliflozin / Metformin HCl XR Tablets	—	COMPLETED	2025-09-24	NCT07266766
Humanis Saglık Anonim Sirketi	Empagliflozin/Linagliptin/Metformin HCL	—	COMPLETED	2025-09-15	NCT07213895
Novo Nordisk	NNC0519-0130	—	COMPLETED	2025-09-10	NCT06513104
Humanis Saglık Anonim Sirketi	Ertugliflozin/Metformin film coated tablets	—	COMPLETED	2025-09-04	NCT07266779
Fujian Shengdi Pharmaceutical Co., Ltd.	HRS9531	—	COMPLETED	2025-09-02	NCT06246175
Nanexa AB	NEX-22A, a prolonged release formulation of liraglutide	—	COMPLETED	2025-07-18	NCT06439056
Novo Nordisk	Semaglutide B	—	COMPLETED	2025-07-10	NCT06642584
Fujian Shengdi Pharmaceutical Co., Ltd.	[14C]HRS9531	—	COMPLETED	2025-06-17	NCT06855147
Fujian Shengdi Pharmaceutical Co., Ltd.	Acetaminophen	Nonsteroidal Anti-inflammatory Drug [EPC]	COMPLETED	2025-06-09	NCT06723691
Humanis Saglık Anonim Sirketi	Empagliflozin + Linagliptin filmcoated tablets	—	COMPLETED	2025-05-14	NCT07039890
Shandong Suncadia Medicine Co., Ltd.	[14C]HRS-7535	—	COMPLETED	2025-04-16	NCT06819488
Pfizer	Rosuvastatin	—	COMPLETED	2025-04-11	NCT06279234
AstraZeneca	AZD5004(Part A)	—	COMPLETED	2025-03-13	NCT06703658
Novo Nordisk	Insulin icodec	—	COMPLETED	2025-03-10	NCT06288412
Humanis Saglık Anonim Sirketi	Empagliflozin + Linagliptin film-coated tablets	—	COMPLETED	2025-03-07	NCT06932159
Novo Nordisk	NNC0487-0111	—	COMPLETED	2025-02-24	NCT06559527
Boryung Pharmaceutical Co., Ltd	BR3409	—	COMPLETED	2025-01-26	NCT06879158
Boryung Pharmaceutical Co., Ltd	BR3006	—	COMPLETED	2025-01-12	NCT06890299
Boryung Pharmaceutical Co., Ltd	BR3006	—	COMPLETED	2025-01-03	NCT06890286
Fujian Shengdi Pharmaceutical Co., Ltd.	HRS9531 injection	—	COMPLETED	2024-12-26	NCT06654960
Boryung Pharmaceutical Co., Ltd	BR1019	—	COMPLETED	2024-12-11	NCT06636877
Chong Kun Dang Pharmaceutical	CKD-383	—	COMPLETED	2024-12-08	NCT06695598
Chong Kun Dang Pharmaceutical	CKD-383	—	COMPLETED	2024-12-07	NCT06695572
Chong Kun Dang Pharmaceutical	CKD-378 25/1000mg	—	COMPLETED	2024-12-07	NCT06709807
Boryung Pharmaceutical Co., Ltd	BR3409	—	COMPLETED	2024-12-07	NCT06879132
Novo Nordisk	NNC0519-0130	—	COMPLETED	2024-11-27	NCT06370819
Sciwind Biosciences USA Co., Ltd.	XW014	—	COMPLETED	2024-11-16	NCT05579314
Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.	Ozempic®	—	COMPLETED	2024-11-14	NCT06634927
Fujian Shengdi Pharmaceutical Co., Ltd.	HRS9531	—	COMPLETED	2024-10-08	NCT06435676
Shandong Suncadia Medicine Co., Ltd.	HRS-1780 tablets	—	COMPLETED	2024-08-13	NCT06495931
Metabolics Pharma	ENT-03	—	COMPLETED	2024-08-12	NCT05925920
Biomed Industries, Inc.	NA-931	—	COMPLETED	2024-08-12	NCT06615700
Shandong Suncadia Medicine Co., Ltd.	HRS-7535(D) Tablets	—	COMPLETED	2024-08-06	NCT06422039
Eli Lilly	LY3209590	—	COMPLETED	2024-07-18	NCT06169982
Sciwind Biosciences APAC CO Pty. Ltd.	T2026	—	COMPLETED	2024-07-13	NCT05184322
Eli Lilly	LY3938577	—	COMPLETED	2024-06-28	NCT06132126
Kallyope Inc.	K-757 and K-833 QD	—	COMPLETED	2024-05-15	NCT06305351
Chong Kun Dang Pharmaceutical	Test: CKD-383, Reference1: Duvie Tab. 0.5mg, Reference2: Jardiance tablets 25 mg, Reference3: GLUCOPHAGE XR TAB. 1000MG	—	COMPLETED	2024-04-29	NCT06483243
Eli Lilly	LY3549492	—	COMPLETED	2024-04-22	NCT05327595
Beijing Dongfang Biotech Co., Ltd.	Exendin-4 Fc fusion protein (JY09) injection	—	COMPLETED	2024-04-15	NCT06247748
Eccogene	ECC5004	—	COMPLETED	2024-04-15	NCT06293742
Jiangsu HengRui Medicine Co., Ltd.	HR17031 injection	—	COMPLETED	2024-04-10	NCT05292495
Novo Nordisk	NNC0519-0130	—	COMPLETED	2024-04-02	NCT05363774

Precision Medicine Biomarkers

All biomarkers →

Biomarkers used for patient selection in Type 2 Diabetes

PR (Progesterone Receptor) (5)

Novel Type 2 Diabetes Drugs by Company (New molecular entities)

6 companies have an FDA-approved novel drug for Type 2 Diabetes.

SANOFI-AVENTIS US 2 drugs

LEXICON PHARMS INC 1 drug

THERACOSBIO 1 drug

ZYDUS LIFESCIENCES 1 drug

Bayer 1 drug

Novo Nordisk 1 drug

Reformulations (32 drugs) Click to expand

Reformulations are FDA-approved versions of existing molecules in new dosage forms (e.g., oral solution vs tablet, extended-release vs immediate-release). They require a new NDA but use an already-proven active ingredient.